Analysts Set Celcuity, Inc. (NASDAQ:CELC) PT at $152.09

Celcuity, Inc. (NASDAQ:CELC) has been given an average rating of “Moderate Buy” by the twelve brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $152.0909.

CELC has been the subject of a number of research reports. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a research report on Thursday, May 28th. Wells Fargo & Company dropped their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Guggenheim restated a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Citizens Jmp upped their target price on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research report on Monday, May 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $157.00 target price on shares of Celcuity in a research report on Friday, May 15th.

Celcuity Stock Performance

CELC opened at $99.95 on Wednesday. The firm has a market cap of $4.87 billion, a P/E ratio of -25.63 and a beta of 0.10. Celcuity has a 1-year low of $11.70 and a 1-year high of $151.02. The company has a 50 day simple moving average of $114.47 and a two-hundred day simple moving average of $110.58. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. Equities analysts forecast that Celcuity will post -3.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock valued at $5,111,950. 13.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celcuity

A number of hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its stake in Celcuity by 20.1% during the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after purchasing an additional 86 shares in the last quarter. Ogorek Anthony Joseph NY ADV raised its stake in Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after purchasing an additional 109 shares in the last quarter. US Bancorp DE raised its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. Intech Investment Management LLC raised its stake in Celcuity by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after purchasing an additional 183 shares in the last quarter. Finally, Aristides Capital LLC raised its stake in Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after purchasing an additional 303 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.